Don't Want to Pass on Genetic Diseases? IVF in Georgia & Full Analysis of Third-Generation PGT Screening

Consultation Scenario: The Choice of a Couple Carrying Thalassemia

"Doctor, my wife and I are both carriers of α-thalassemia. We had one PGT cycle domestically, but only 2 blastocysts were formed, and after testing, none were transferable. We are considering trying again in Georgia. What do you think?" This is an increasingly common type of consultation in clinics. Families with a clear risk of transmitting genetic diseases, after facing embryo screening difficulties domestically, are starting to look towards overseas reproductive centers. Georgia has become one option due to its legal openness to PGT technology and relatively accessible costs. However, whether this path is suitable for all genetic disease scenarios needs to be analyzed from a medical foundation.

Core Technical Logic of IVF in Georgia for Blocking Genetic Diseases

Georgia's assisted reproduction laws permit preimplantation genetic testing (PGT) of embryos, providing the technical basis for blocking genetic diseases. PGT technology includes three main branches:

In Georgia, all three types of technology can be legally performed, and the law does not impose excessive restrictions on indications. As long as there are medical indications and genetic counseling confirmation, the process can proceed. This differs from some countries where PGT-M is limited only to severe genetic diseases.

When is Choosing IVF in Georgia Suitable for Blocking Genetic Diseases?

Not all carriers of genetic diseases are suitable for this path. From a medical screening perspective, suitable individuals have the following characteristics:

• Clear pathogenic gene with mature testing technology: Such as thalassemia, hemophilia, hereditary deafness, spinal muscular atrophy, etc., where the gene locus is clear and a PGT-M testing protocol can be established.
• Chromosomal structural abnormalities: Such as balanced translocation, Robertsonian translocation, where PGT-SR can effectively screen for structurally normal embryos.
• Previous PGT cycle yielded embryos but no transferable ones: Indicates a high proportion of embryos affected by the genetic issue, requiring a larger embryo base for screening. The cost of embryo culture and testing in Georgia is relatively manageable.
• Woman has adequate ovarian reserve: PGT cycles require a certain number of blastocysts to increase the probability of finding a transferable embryo. An AMH level above 1.2 ng/mL and an antral follicle count (AFC) greater than 8 are recommended.
• Clear ethical acceptance of embryo genetic testing: A clear understanding that PGT is a screening tool, not a treatment, and acceptance of possible outcomes after embryo screening (e.g., no transferable embryos).

When is it Unsuitable or Requires Careful Evaluation?

The following situations require more careful evaluation before choosing IVF in Georgia:

• Complex inheritance pattern or unclear gene locus: Such as some polygenic disorders (diabetes, hypertension, etc.), de novo mutations where linkage analysis cannot be established, making PGT-M probe design impossible.
• Severely diminished ovarian reserve in the woman: AMH below 0.8 ng/mL, or fewer than 3 eggs retrieved in a previous stimulation cycle, leading to a low probability of forming blastocysts and an extremely low chance of obtaining a transferable embryo after PGT.
• Both partners are carriers of the same genetic disease with a high frequency of the pathogenic gene: For example, if both are carriers of β-thalassemia, theoretically 25% of embryos will be severely affected, 50% carriers, and only 25% completely normal. A sufficient number of blastocysts is needed to screen for normal embryos.
• Expectations of PGT technology exceed medical boundaries: PGT cannot detect all genetic diseases, nor can it predict future non-medical traits of the embryo such as intelligence, height, or personality.
• Lack of standardized genetic counseling and carrier screening: Entering an IVF cycle directly could lead to errors in test protocol design or missed detection.

A Doctor's Perspective on the True Boundaries of PGT Technology

As a reproductive physician, a core fact must be clarified: PGT is a screening technology, not a treatment. It cannot repair genetic problems in an embryo; it can only identify which embryos do not carry the known pathogenic gene. For autosomal recessive disorders, the screening goal is to find completely normal embryos (0 copies of the pathogenic gene) or carrier embryos (1 copy), the latter typically not developing the disease. For autosomal dominant disorders, the goal is to find embryos without the pathogenic gene mutation. The accuracy of PGT depends on the sensitivity of the testing platform, the quality of probe design, and the number of cells biopsied from the embryo. Currently, the accuracy of PGT-M on major international platforms ranges from 97% to 99%, with a 1% to 3% risk of testing error or allele drop-out (ADO). This means that prenatal diagnosis (amniocentesis) is still required after transfer for confirmation. This is not unique to Georgia but is a shared boundary of PGT technology globally.

Key Differences Between Georgia and Other Countries

Choosing Georgia as a PGT destination requires an objective look at its differences compared to domestic options and other countries:

Georgia's differentiated advantages include: fewer legal restrictions on PGT indications, shorter cycle waiting times, and overall costs between those in China and the US. However, disadvantages include: variable laboratory quality, reliance on third-party international labs for genetic testing (e.g., Reprogenetics, Igenomix in the US), logistical risks with sample transport, and less mature medical dispute resolution mechanisms compared to established countries.

Easily Overlooked Detail: Genetic Counseling and Probe Design

The success of PGT-M depends on customizing genetic testing probes for each couple. This process requires first confirming the pathogenic gene in the proband (affected family member) or both partners. If there is no proband and both partners are only carriers, the pathogenic locus must be identified first through Sanger sequencing or whole exome sequencing. This step usually takes 4-8 weeks and must be completed before starting the IVF cycle. Many families overlook this lead time, assuming they can start ovarian stimulation immediately upon arrival in Georgia. In reality, if genetic reports are incomplete, gene loci are unconfirmed, or probe design is difficult (e.g., high GC content, interference from homologous sequences), the entire cycle may be delayed. It is recommended to complete the following genetic preparations at least 2 months before departure:

• Complete family history of genetic diseases (within three generations)
• Carrier screening reports for both partners (for the target genetic disease)
• Genetic testing report of the proband (if available)
• Genetic counseling records and PGT feasibility assessment
• Peripheral blood samples required for probe design (some labs require samples sent in advance)

Common Pitfall: Lab Selection and Embryo Transport Risks

There are approximately 30-40 reproductive centers in Georgia, but fewer than 10 have independent genetic labs or stable collaborations with PGT testing institutions. Some smaller centers send biopsied samples to testing facilities in Russia or Europe, where logistics can cause delays, loss, or temperature abnormalities. When choosing a center, confirm the following three points:

• Is the biopsy performed by the center's own embryologist? Biopsy experience directly impacts the embryo's subsequent developmental potential; inexperienced biopsy can cause embryo damage or test failure.
• Is the third-party lab for PGT testing clearly qualified? Prioritize centers collaborating with CAP or CLIA certified laboratories.
• Does sample transport have full cold chain and tracking? Request logistics records and temperature monitoring data.

Additionally, some institutions bundle testing fees into the cycle cost under the guise of "all-inclusive PGT," but actual testing quality is unguaranteed. It is advisable to list genetic testing fees separately and confirm the fee schedule and reporting timeline directly with the testing laboratory.

Actual Process: Complete Timeline from Consultation to Transfer

Below is a typical timeline for a PGT cycle in Georgia aimed at blocking genetic diseases (using monogenic disorders as an example):

The entire cycle from starting stimulation to receiving test results takes about 6-8 weeks. Adding the lead time for genetic assessment, the total time from preparation to transfer is about 3-5 months. If the number of embryos is insufficient and another stimulation cycle is needed, the timeline will be extended accordingly.

Handling Special Situations: Low Embryo Count or Inconclusive Test Results

In clinical practice, about 30%-40% of PGT cycles result in "no transferable embryos." For carriers of genetic diseases, this proportion can be higher, especially when the pathogenic gene reduces embryo developmental potential (e.g., some mitochondrial diseases or DNA repair deficiency genes). If the first cycle yields only a few blastocysts and none are normal after testing, review with your doctor:

• Was a sufficient number of eggs retrieved? Does the stimulation protocol need adjustment?
• Is there high DNA fragmentation in sperm or eggs affecting embryo development?
• Could transfer of mosaic embryos be considered? Some mosaic embryos may develop normally, but genetic counseling is needed to assess the risk.
• Could egg or sperm donation be considered as a backup plan?

For carriers of chromosomal structural abnormalities (e.g., balanced translocation), the probability of PGT-SR screening for normal or balanced embryos is about 30%-60%, depending on the translocation type and breakpoints. If two consecutive cycles yield no transferable embryos, consider accepting egg donation or changing the genetic blocking strategy.

Required Materials and Medical Documents

Ensure the following documents are prepared before departure to avoid delays in Georgia due to incomplete materials:

• Valid passports for both partners (valid for over 6 months) and visas
• All original genetic test reports (Chinese + English translation, stamped)
• Carrier screening reports (including gene locus information)
• Records of previous PGT cycles (if any): stimulation protocol, number of eggs retrieved, number of blastocysts, test results
• Infectious disease screening reports: HIV, Hepatitis B, Hepatitis C, Syphilis, CMV, Rubella, etc. (valid for 6 months)
• Woman's basic fertility assessment: AMH, FSH, LH, E2, antral follicle count (ultrasound report)
• Male semen analysis report (including sperm DNA fragmentation, recommended)
• Genetic counseling records (if any)

Risk Reminder: Limitations of PGT Technology and Medical Decision Boundaries

Before concluding, several core risks related to blocking genetic diseases need to be clarified:

• PGT testing cannot cover all genetic diseases: Current PGT-M can only detect known mutations in known pathogenic genes. It cannot detect de novo mutations, non-coding region mutations, or diseases with complex inheritance patterns.
• Embryo mosaicism can lead to misdiagnosis: Biopsy takes 5-10 trophectoderm cells. If the embryo is mosaic (some cells normal, some abnormal), the test result may not reflect the overall status of the embryo. An abnormal embryo may continue to develop or miscarry after transfer.
• Prenatal diagnosis is still required after pregnancy: PGT is not a diagnostic technique. Amniocentesis or chorionic villus sampling after transfer is a necessary step to confirm the fetal genetic status.
• Georgia's medical regulatory system differs from domestic systems: It is recommended to choose a reproductive center with JCI or ISO certification and confirm that the center has a clear medical dispute resolution process.
• Risk of cost overrun: If a transferable embryo is not obtained in one cycle, the cost of repeated stimulation cycles needs to be planned in advance. Some centers offer installment services for "embryo freezing + testing," but the overall budget should be prepared for 2-3 cycles.

For families at risk of transmitting genetic diseases, choosing IVF in Georgia is a medically sound path, provided that the genetic diagnosis is clear, the laboratory choice is prudent, and there is an objective understanding of the technology's boundaries. Before making a final decision, it is recommended to consult with both a domestic genetic counselor and a reproductive physician to ensure accurate judgment of PGT indications and avoid medical decision-making bias due to information asymmetry.